Phase 1/2 × Active not recruiting × Sarcoma × Clear all
NCT03899792 2026-01-06

LIBRETTO-121

Eli Lilly and Company

Phase 1/2 Active not recruiting
36 enrolled 13 charts 4 FDA
NCT03162536 2025-09-08

ARQ 531-101

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1/2 Active not recruiting
190 enrolled
NCT05864144 2025-08-15

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Sensei Biotherapeutics, Inc.

Phase 1/2 Active not recruiting
98 enrolled
NCT04140526 2025-05-23

PRESERVE-001

OncoC4, Inc.

Phase 1/2 Active not recruiting
733 enrolled